VXRT RSI Chart
Last 7 days
2.9%
Last 30 days
-33.3%
Last 90 days
-39.0%
Trailing 12 Months
-17.2%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 697.0K | 2.1M | 4.2M | 7.4M |
2022 | 471.0K | 359.0K | 159.0K | 107.0K |
2021 | 1.6M | 1.2M | 1.2M | 892.0K |
2020 | 7.4M | 7.8M | 7.6M | 4.0M |
2019 | 8.1M | 7.5M | 7.7M | 9.9M |
2018 | 5.0M | 3.8M | 3.2M | 4.2M |
2017 | 5.3M | 3.2M | 6.6M | 5.8M |
2016 | 0 | 11.5M | 9.4M | 7.4M |
2015 | 23.5M | 8.4M | 13.6M | 0 |
2014 | 69.5M | 68.7M | 53.6M | 38.5M |
2013 | 24.9M | 33.6M | 44.4M | 52.5M |
2012 | 14.0M | 10.9M | 11.2M | 19.5M |
2011 | 30.4M | 29.3M | 18.1M | 16.1M |
2010 | 0 | 18.7M | 26.8M | 35.0M |
2009 | 0 | 0 | 0 | 10.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 28, 2024 | cummings james f. | sold (taxes) | -4,279 | 1.3 | -3,292 | chief medical officer |
Mar 28, 2024 | tucker sean | sold (taxes) | -5,072 | 1.3 | -3,902 | svp, chief scientific officer |
Mar 18, 2024 | lee phillip e | acquired | - | - | 90,000 | chief financial officer |
Mar 18, 2024 | cummings james f. | acquired | - | - | 90,000 | chief medical officer |
Mar 18, 2024 | lo steven | acquired | - | - | 250,000 | president, chief exec officer |
Mar 18, 2024 | tucker sean | acquired | - | - | 90,000 | svp, chief scientific officer |
Mar 18, 2024 | berg edward b | acquired | - | - | 90,000 | svp, general counsel |
Feb 02, 2024 | berg edward b | sold (taxes) | -11,064 | 1.2 | -9,220 | svp, general counsel |
Feb 02, 2024 | cummings james f. | sold (taxes) | -9,558 | 1.2 | -7,965 | chief medical officer |
Feb 02, 2024 | tucker sean | sold (taxes) | -11,064 | 1.2 | -9,220 | svp, chief scientific officer |
Which funds bought or sold VXRT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 172 | 231,840 | 276,598 | -% |
May 07, 2024 | Headlands Technologies LLC | new | - | 11,977 | 11,977 | -% |
May 06, 2024 | Fi3 FINANCIAL ADVISORS, LLC | unchanged | - | 4,058 | 18,951 | 0.01% |
May 06, 2024 | Parallel Advisors, LLC | reduced | -21.67 | 1,706 | 3,900 | -% |
May 03, 2024 | Larson Financial Group LLC | unchanged | - | 114 | 203 | -% |
May 03, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -77.49 | -137,000 | 143,000 | 0.01% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | BNP PARIBAS FINANCIAL MARKETS | reduced | -20.58 | 1,525 | 3,426 | -% |
Apr 30, 2024 | Concord Wealth Partners | unchanged | - | 55.00 | 98.00 | -% |
Apr 30, 2024 | MACROVIEW INVESTMENT MANAGEMENT LLC | unchanged | - | 263 | 470 | -% |
Unveiling Vaxart Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Vaxart Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 46.7B | 6.8B | -7.83 | 6.82 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.3B | 2.0B | -58.01 | 9.62 | ||||
BMRN | 15.5B | 2.5B | 75.6 | 6.28 | ||||
INCY | 12.0B | 3.8B | 16.12 | 3.19 | ||||
MID-CAP | ||||||||
BBIO | 5.2B | 107.9M | -9.48 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.3 | 9.79 | ||||
AXSM | 3.6B | 251.0M | -12.15 | 14.35 | ||||
ARWR | 3.1B | 240.7M | -10.53 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.95 | 3.88 | ||||
SMALL-CAP | ||||||||
CPRX | 1.7B | 411.3M | 26.68 | 4.22 | ||||
NVAX | 625.6M | 983.7M | -1.15 | 0.64 | ||||
CRBP | 451.6M | 881.7K | -13.38 | 481.06 | ||||
INO | 257.1M | 4.9M | -1.9 | 52.83 | ||||
IBIO | 6.6M | 2.1M | -0.24 | 2.14 |
Vaxart Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 54.5% | 3,245,000 | 2,101,000 | 1,358,000 | 675,000 | 22,000 | - | - | 85,000 | 74,000 | 200,000 | 112,000 | 506,000 | 356,000 | 265,000 | 523,000 | 2,902,000 | 3,916,000 | 454,000 | 85,000 | 5,407,000 | 1,767,000 |
Operating Expenses | 1.1% | 20,145,000 | 19,923,000 | 24,411,000 | 26,247,000 | 31,160,000 | 29,426,000 | 29,247,000 | 24,861,000 | 24,289,000 | 17,451,000 | 15,887,000 | 16,017,000 | 13,717,000 | 7,854,000 | 9,049,000 | 3,596,000 | 9,542,000 | 5,168,000 | 5,082,000 | 5,855,000 | 5,953,000 |
S&GA Expenses | 10.5% | 5,440,000 | 4,921,000 | 5,598,000 | 6,625,000 | 6,447,000 | 6,960,000 | 9,321,000 | 6,658,000 | 5,754,000 | 5,042,000 | 5,150,000 | 5,944,000 | 5,126,000 | 4,190,000 | 3,896,000 | 1,990,000 | 1,331,000 | 1,455,000 | 1,375,000 | 2,026,000 | 1,226,000 |
R&D Expenses | -2.0% | 14,705,000 | 15,002,000 | 18,813,000 | 19,622,000 | 20,459,000 | 22,466,000 | 19,926,000 | 18,203,000 | 15,530,000 | 12,409,000 | 10,737,000 | 10,073,000 | 8,591,000 | 4,616,000 | 5,114,000 | 1,542,000 | 3,291,000 | 3,713,000 | 3,707,000 | 3,829,000 | 4,474,000 |
EBITDA Margin | 48.7% | -9.97 | -19.42 | -45.33 | -144 | -952 | -625 | -245 | -159 | -74.16 | -50.74 | -40.71 | -26.47 | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27,000 | 84,000 | 97,000 | 107,000 | 119,000 |
Income Taxes | 346.2% | 174,000 | 39,000 | 19,000 | 29,000 | 16,000 | 16,000 | 15,000 | 20,000 | 18,000 | 21,000 | 30,000 | 38,000 | 33,000 | 26,000 | 26,000 | 153,000 | 196,000 | 31,000 | 13,000 | 250,000 | 80,000 |
Earnings Before Taxes | 0.9% | -17,201,000 | -17,361,000 | -22,531,000 | -25,111,000 | -23,902,000 | -29,293,000 | -29,415,000 | -25,081,000 | -20,746,000 | -17,562,000 | -16,086,000 | -15,969,000 | -13,828,000 | -8,059,000 | -8,951,000 | -1,144,000 | -6,213,000 | -5,229,000 | -5,624,000 | -1,089,000 | -4,822,000 |
EBT Margin | 47.9% | -11.14 | -21.39 | -49.07 | -154 | -1,006 | -657 | -258 | -168 | -78.88 | -54.04 | -43.54 | -28.37 | - | - | - | - | - | - | - | - | - |
Net Income | 0.1% | -17,375,000 | -17,400,000 | -22,550,000 | -25,140,000 | -23,918,000 | -29,309,000 | -29,430,000 | -25,101,000 | -20,764,000 | -17,583,000 | -16,116,000 | -16,007,000 | -13,861,000 | -8,085,000 | -8,977,000 | -1,297,000 | -6,409,000 | -5,260,000 | -5,637,000 | -1,339,000 | -4,902,000 |
Net Income Margin | 47.8% | -11.18 | -21.42 | -49.11 | -154 | -1,007 | -657 | -258 | -168 | -79.00 | -54.15 | -43.64 | -28.44 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 12.2% | -13,417,000 | -15,283,000 | -17,925,000 | -25,699,000 | -33,053,000 | -16,643,000 | -28,225,000 | -26,459,000 | -16,829,000 | -15,591,000 | -15,362,000 | -17,207,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -13.1% | 92.00 | 106 | 123 | 130 | 154 | 175 | 181 | 200 | 221 | 241 | 229 | 206 | 153 | 155 | 64.00 | 53.00 | 37.00 | 43.00 | 37.00 | 36.00 | 35.00 |
Current Assets | -20.3% | 46.00 | 57.00 | 71.00 | 76.00 | 99.00 | 120 | 138 | 154 | 169 | 192 | 189 | 175 | 129 | 136 | 46.00 | 34.00 | 18.00 | 21.00 | 17.00 | 15.00 | 15.00 |
Cash Equivalents | 4.6% | 35.00 | 33.00 | 43.00 | 48.00 | 44.00 | 51.00 | 91.00 | 123 | 144 | 167 | 165 | 157 | 127 | 133 | 44.00 | 30.00 | 14.00 | 20.00 | 16.00 | 8.00 | 12.00 |
Net PPE | -9.2% | 12.00 | 13.00 | 14.00 | 14.00 | 16.00 | 12.00 | 9.00 | 8.00 | 7.00 | 5.00 | 4.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 2.00 | 1.00 |
Goodwill | 0.2% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | -0.3% | 34.00 | 34.00 | 38.00 | 40.00 | 43.00 | 53.00 | 38.00 | 34.00 | 34.00 | 36.00 | 29.00 | 30.00 | 29.00 | 23.00 | 24.00 | 21.00 | 24.00 | 24.00 | 21.00 | 24.00 | 24.00 |
Current Liabilities | 21.8% | 14.00 | 11.00 | 14.00 | 16.00 | 18.00 | 22.00 | 16.00 | 11.00 | 11.00 | 13.00 | 13.00 | 12.00 | 12.00 | 10.00 | 11.00 | 7.00 | 9.00 | 9.00 | 7.00 | 9.00 | 7.00 |
Shareholder's Equity | -19.2% | 58.00 | 72.00 | 85.00 | 90.00 | 111 | 122 | 143 | 166 | 188 | 205 | 200 | 176 | 123 | 132 | 40.00 | 31.00 | 13.00 | 19.00 | 16.00 | 13.00 | 11.00 |
Retained Earnings | -4.4% | -409 | -392 | -374 | -352 | -327 | -303 | -273 | -244 | -219 | -198 | -181 | -164 | -148 | -135 | -126 | -117 | -116 | -110 | -104 | -99.35 | -97.99 |
Additional Paid-In Capital | 0.9% | 468 | 464 | 460 | 442 | 438 | 426 | 417 | 411 | 407 | 404 | 381 | 341 | 272 | 267 | 167 | 142 | 130 | 125 | 119 | 111 | 109 |
Accumulated Depreciation | - | 7.00 | - | - | - | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | 0.9% | 153 | 152 | 152 | 136 | 134 | 126 | 126 | 126 | 126 | 120 | 121 | 115 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 110 | - | - | - | 394 | - | - | - | 913 | - | - | - | 842 | - | - | - | 8.00 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 9.9% | -13,521 | -15,001 | -17,471 | -24,460 | -29,152 | -14,615 | -25,899 | -25,113 | -15,814 | -14,267 | -13,159 | -16,592 | -10,766 | -9,255 | -521 | -3,208 | -3,792 | -4,328 | -317 | -4,653 | -5,702 |
Share Based Compensation | -3.3% | 3,715 | 3,843 | 3,927 | 2,647 | 3,393 | 3,643 | 3,421 | 3,130 | 2,913 | 2,099 | 2,604 | 1,251 | 487 | 915 | 2,860 | 96.00 | 137 | 146 | 180 | 164 | 152 |
Cashflow From Investing | 203.9% | 15,104 | 4,970 | -1,583 | 25,461 | 15,801 | -31,073 | -8,875 | 3,732 | -8,177 | -4,412 | -15,949 | -20,559 | -902 | -308 | -9.00 | -1.00 | -12.00 | -127 | -159 | -552 | -195 |
Cashflow From Financing | -725.0% | -66.00 | -8.00 | 13,897 | 1,420 | 8,596 | 4,988 | 2,838 | 1,040 | 505 | 20,644 | 37,063 | 67,592 | 5,100 | 98,613 | 15,059 | 19,542 | -2,228 | 7,755 | 8,310 | 2,123 | -519 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 7,379 | $ 107 |
Operating expenses: | ||
Research and development | 68,142 | 81,054 |
General and administrative | 22,584 | 29,386 |
Impairment of intangible assets | 0 | 4,254 |
Total operating expenses | 90,726 | 114,694 |
Operating loss | (83,347) | (114,587) |
Other income (expense): | ||
Interest income | 2,652 | 1,247 |
Non-cash interest expense related to sale of future royalties | (1,447) | (1,305) |
Gain on remeasurement of future royalty liability | 0 | 6,960 |
Other expense, net | (62) | (6) |
Loss before income taxes | (82,204) | (107,691) |
Provision for income taxes | 261 | 67 |
Net loss | $ (82,465) | $ (107,758) |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | $ (0.57) | $ (0.84) |
Shares used to compute net loss per share, basic and diluted (in shares) | 144,819,781 | 127,683,813 |
Comprehensive loss: | ||
Net loss | $ (82,465) | $ (107,758) |
Unrealized gain (loss) on available-for-sale investments, net of tax | 298 | (225) |
Comprehensive loss | (82,167) | (107,983) |
Non Cash Royalty Revenue [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | 3,920 | 107 |
Grant [Member] | ||
Revenue from Contract with Customer, Including Assessed Tax | $ 3,459 | $ 0 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash, cash equivalents and restricted cash | $ 34,755 | $ 46,013 |
Short-term investments | 4,958 | 49,704 |
Accounts receivable | 3,008 | 20 |
Prepaid expenses and other current assets | 2,815 | 3,714 |
Total current assets | 45,536 | 99,451 |
Property and equipment, net | 11,731 | 15,585 |
Right-of-use assets, net | 24,840 | 25,715 |
Intangible assets, net | 4,289 | 5,020 |
Goodwill | 4,508 | 4,508 |
Other long-term assets | 926 | 3,568 |
Total assets | 91,830 | 153,847 |
Current liabilities: | ||
Accounts payable | 1,584 | 5,514 |
Deferred grant revenue | 0 | 2,000 |
Other accrued current liabilities | 5,634 | 8,084 |
Current portion of operating lease liability | 2,703 | 2,228 |
Current portion of liability related to sale of future royalties | 3,803 | 95 |
Total current liabilities | 13,724 | 17,921 |
Operating lease liability, net of current portion | 17,385 | 19,477 |
Liability related to sale of future royalties, net of current portion | 2,623 | 5,621 |
Other long-term liabilities | 293 | 231 |
Total liabilities | 34,025 | 43,250 |
Commitments and contingencies (Note 9) | ||
Stockholders’ equity: | ||
Preferred Stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of December 31, 2023 or 2022 | 0 | 0 |
Common Stock: $0.0001 par value; 250,000,000 shares authorized as of December 31, 2023 and 2022; 153,959,853 shares issued and 153,452,833 shares outstanding as of December 31, 2023 and 134,199,429 shares issued and outstanding as of December 31, 2022 | 15 | 13 |
Additional paid-in capital | 467,731 | 437,992 |
Treasury Stock at cost, 507,020 shares and none as of December 31, 2023 and 2022, respectively | (366) | 0 |
Accumulated deficit | (409,574) | (327,109) |
Accumulated other comprehensive loss | (1) | (299) |
Total stockholders’ equity | 57,805 | 110,597 |
Total liabilities and stockholders’ equity | $ 91,830 | $ 153,847 |